Market News AIOpen the app

BofA Securities started following Viridian Therapeutics and says to buy its stock, noting strong sales for Lumvoa.

OpinionRead the original at marketscreener.com
Good for VRDN

Viridian's Lumvoa brought in $25 million in third-quarter sales, versus about $5 million expected, and enrolled over 100 patients. That supports growth, though the forecast of more than 70% market share and the 2027 billing code are not results yet.

VRDN · Viridian Therapeutics

AI read · Good for VRDN

The AI's read

The reported sales and patient count suggest Lumvoa is gaining use. BofA also sees it as a credible rival to Tepezza, which could help Viridian reach more patients. Its market-share estimate and 2027 billing-code expectation are forecasts, not completed outcomes. The reported sales beat is the clearest reason for a favorable read.

AMGN · Amgen

AI read · Bad for AMGN

The connection

Amgen's Tepezza faces Lumvoa, which BofA describes as a credible rival with similar results and a shorter treatment course. The forecast of more than 70% market share is not yet achieved, but the stated comparison points to a competitive risk for Amgen.

Get alerts for VRDN

Follow Viridian Therapeutics (VRDN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VRDN
Free on the App Store and Google Play, or on the web.